<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01915277</url>
  </required_header>
  <id_info>
    <org_study_id>PHN-DEX</org_study_id>
    <nct_id>NCT01915277</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics</brief_title>
  <official_title>A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase I study is to determine the safety of a drug called dexmedetomidine
      (DEX) as part of a balanced general anesthetic and sedative strategy for neonates and infants
      undergoing corrective cardiac surgery that requires the use of cardiopulmonary bypass for
      congenital cardiac problems. This study will also design and validate a dosing schema for the
      use of DEX as described above.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2014</start_date>
  <completion_date type="Actual">October 17, 2017</completion_date>
  <primary_completion_date type="Actual">October 16, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of a safety event that is possibly, probably or definitely related to DEX administration</measure>
    <time_frame>Within 4 hours after DEX adminstration</time_frame>
    <description>The occurrence of any of the following that is possibly, probably, or definitely related to DEX administration:
Bradycardia
Heart block
Junctional rhythm
Hypotension
Excessive sedation
Cardiac arrest or ECMO cannulation
Serious Adverse Event (SAE)
Both the DEX dose, and DEX exposure will be assessed for associations with the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of DEX</measure>
    <time_frame>Intraoperatively and up to 36 hours post-operatively</time_frame>
    <description>Plasma concentrations of dex obtained intraoperatively and up to 36 hours post-operatively will be used to create drug dosing models. These models will then be evaluated to determine how effective they are at achieving targeted plasma concentration levels.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Transposition of the Great Arteries</condition>
  <condition>Tetralogy of Fallot</condition>
  <condition>Ventricular Septal Defect</condition>
  <arm_group>
    <arm_group_label>Neonate dosing cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonate dexmedetomidine dosing cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neonate dosing cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonate dexmedetomidine dosing cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neonate dosing cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonate dexmedetomidine dosing cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neonate dosing cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonate dexmedetomidine dosing cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neonate dosing cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonate dexmedetomidine dosing cohort 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant dosing cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant dexmedetomidine dosing cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant dosing cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant dexmedetomidine dosing cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant dosing cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant dexmedetomidine dosing cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant dosing cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant dexmedetomidine dosing cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant dosing cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant dexmedetomidine dosing cohort 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>Neonate dosing cohort 1</arm_group_label>
    <arm_group_label>Neonate dosing cohort 2</arm_group_label>
    <arm_group_label>Neonate dosing cohort 3</arm_group_label>
    <arm_group_label>Neonate dosing cohort 4</arm_group_label>
    <arm_group_label>Neonate dosing cohort 5</arm_group_label>
    <arm_group_label>Infant dosing cohort 1</arm_group_label>
    <arm_group_label>Infant dosing cohort 2</arm_group_label>
    <arm_group_label>Infant dosing cohort 3</arm_group_label>
    <arm_group_label>Infant dosing cohort 4</arm_group_label>
    <arm_group_label>Infant dosing cohort 5</arm_group_label>
    <other_name>Precedex, dexmedetomidine HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, age 0 to 180 days at the time of surgery.

          2. Diagnosis of: D-transposition of the great arteries (with or without ventricular
             septal defect), or tetralogy of Fallot, or ventricular septal defect (with or without
             associated atrial septal defect and/or patent ductus arteriosus)

          3. Scheduled for complete corrective two-ventricle surgical repair with cardiopulmonary
             bypass.

        Exclusion Criteria:

          -  1. Less than 37 completed weeks' gestational age at birth for the Neonatal age group
             (0-21 days); less than 36 completed weeks' gestational age at birth for the Infant age
             group (22-180 days).

             2. Enrollment in the PHN Collaborative Learning Study, if tetralogy of Fallot 91-180
             days of age only.

             3. Known or suspected hepatic dysfunction; AST and ALT &gt;3X upper limit of normal at
             the time of screening within 72 hours of operation.

             4. Known or suspected renal dysfunction; serum creatinine &gt; 0.8 mg/dL after 7 days of
             age, &gt;1.2 mg/dL if &lt;7 days of age, within 72 hours of operation.

             5. Preoperative administration of DEX or clonidine within 72 hours of operation.

             6. Major congenital anomaly(ies) outside the cardiovascular system that in the
             investigator's opinion would potentially affect safety or pharmacokinetics.

             7. Preoperative central nervous system injury resulting in clinical signs and
             symptoms: coma, seizures, hemiparesis.

             8. Planned period of deep hypothermic circulatory arrest. 9. History of second or
             third degree heart block. 10. Sinus or junctional bradycardia below 80 BPM sustained
             for greater than 15 minutes within 72 hours of operation. 11. Junctional rhythm
             sustained for greater than 15 minutes within 72 hours of operation.

             12. Hypotension defined as mean arterial blood pressure below 35 mm Hg for 0-21 day
             old neonatal patients, and below 40 mm Hg for 22-180 day old infant patients sustained
             for greater than 15 minutes within 72 hours of operation.

             13. History of cardiac arrest or ECMO cannulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>180 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2013</study_first_submitted>
  <study_first_submitted_qc>July 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric corrective cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
    <mesh_term>Heart Septal Defects, Ventricular</mesh_term>
    <mesh_term>Transposition of Great Vessels</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

